首页 > 最新文献

The Journal of Pediatric Academy最新文献

英文 中文
Late Diagnosed Argininemia 晚期诊断精氨酸血症
Pub Date : 2021-04-30 DOI: 10.51271/jpea-2021-0104
Sezai Arslan, Ümmü Alakuş Sarı, Banu Kadıoğlu Yılmaz, F. Kardaş, Füsun Ferda Erdoğan, M. Kendirci
Ammonia; It is a toxic molecule for the central nervous system resulting from the catabolism of proteins. Its excretion is provided with the urea cycle. Argininemia is a rare subtype of urea cycle disorders. Arginase enzyme catalyzes the last stage of the urea cycle, arginine; urea and ornithine are broken down. The decrease in arginase 1 (ARG1) enzyme activity is responsible for argininemia. The most common presenting symptoms of patients diagnosed with argininemia are progressive spastic diplegia, regression in developmental stages, choreoathetosis, hepatomegaly and seizures. The diagnosis of the disease can be made by detecting the elevation of arginine in body fluids together with the increase in serum ammonia. Neurological findings of these patients can be confused with cerebral palsy. In this case report, we wanted to present a patient with argininemia who was followed up with a diagnosis of cerebral palsy for a long time. Early diagnosis, restricted protein and arginine diet are life-saving in this disease. Argininemia should be kept in mind in patients with unexplained neuromotor retardation.
氨;它是一种由蛋白质分解代谢产生的中枢神经系统的有毒分子。其排泄具有尿素循环。精氨酸血症是尿素循环障碍的一种罕见亚型。精氨酸酶催化尿素循环的最后阶段精氨酸;尿素和鸟氨酸被分解。精氨酸酶1 (ARG1)酶活性的降低是精氨酸血症的原因。精氨酸血症患者最常见的症状是进行性痉挛性双瘫、发育阶段倒退、舞蹈病、肝肿大和癫痫发作。该病的诊断可以通过检测体液中精氨酸的升高和血清氨的升高来进行。这些患者的神经学表现可能与脑瘫混淆。在这个病例报告中,我们想提出一个精氨酸血症的病人,他被随访诊断为脑瘫很长一段时间。早期诊断,限制蛋白质和精氨酸饮食是挽救生命的疾病。有不明原因的神经运动迟缓的患者应注意精氨酸血症。
{"title":"Late Diagnosed Argininemia","authors":"Sezai Arslan, Ümmü Alakuş Sarı, Banu Kadıoğlu Yılmaz, F. Kardaş, Füsun Ferda Erdoğan, M. Kendirci","doi":"10.51271/jpea-2021-0104","DOIUrl":"https://doi.org/10.51271/jpea-2021-0104","url":null,"abstract":"Ammonia; It is a toxic molecule for the central nervous system resulting from the catabolism of proteins. Its excretion is provided with the urea cycle. Argininemia is a rare subtype of urea cycle disorders. Arginase enzyme catalyzes the last stage of the urea cycle, arginine; urea and ornithine are broken down. The decrease in arginase 1 (ARG1) enzyme activity is responsible for argininemia. The most common presenting symptoms of patients diagnosed with argininemia are progressive spastic diplegia, regression in developmental stages, choreoathetosis, hepatomegaly and seizures. The diagnosis of the disease can be made by detecting the elevation of arginine in body fluids together with the increase in serum ammonia. Neurological findings of these patients can be confused with cerebral palsy. In this case report, we wanted to present a patient with argininemia who was followed up with a diagnosis of cerebral palsy for a long time. Early diagnosis, restricted protein and arginine diet are life-saving in this disease. Argininemia should be kept in mind in patients with unexplained neuromotor retardation.","PeriodicalId":118905,"journal":{"name":"The Journal of Pediatric Academy","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117150383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pediatric Takayasu Vasculitis with Extensive Vascular Involvement 广泛受累的小儿高须血管炎
Pub Date : 2020-12-27 DOI: 10.38092/JPA-2020-236659
Şeyda Doğantan, Sema Nur Taşkın, Sümeyra Özdemir-Çiçek, Z. Karaman, Aysenur Pac-Kisaarslan, M. Poyrazoğlu
Doğantan Ş, Taikın SN, Özdemir ÇiçekS, Kahraman ZF, Paç Kısaarslan A, Poyrazoğlu MH. Pediatric Takayasu Vasculitis with Extensive Vascular Involvement. J Pediatr Acad 2020; 1: 105-106.
{"title":"Pediatric Takayasu Vasculitis with Extensive Vascular Involvement","authors":"Şeyda Doğantan, Sema Nur Taşkın, Sümeyra Özdemir-Çiçek, Z. Karaman, Aysenur Pac-Kisaarslan, M. Poyrazoğlu","doi":"10.38092/JPA-2020-236659","DOIUrl":"https://doi.org/10.38092/JPA-2020-236659","url":null,"abstract":"Doğantan Ş, Taikın SN, Özdemir ÇiçekS, Kahraman ZF, Paç Kısaarslan A, Poyrazoğlu MH. Pediatric Takayasu Vasculitis with Extensive Vascular Involvement. J Pediatr Acad 2020; 1: 105-106.","PeriodicalId":118905,"journal":{"name":"The Journal of Pediatric Academy","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114383674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Treatment Outcomes in Children with Medulloblastoma 儿童髓母细胞瘤的治疗结果
Pub Date : 2020-12-27 DOI: 10.38092/JPA-2020-909489
Buket Kara, H. Akbaş, Mürsel Düzova, H. Karabağlı, Y. Köksal
Background: Medulloblastoma is the most common central nervous system tumor in childhood. This study aims to evaluate the clinical features, treatments, and outcomes of pediatric patients diagnosed with medulloblastomaMaterials and Method:Between 2006 and 2019, the medical records of children with medulloblastoma were reviewed retrospectively. Patients who died after surgery, before chemotherapy or radiotherapy were not included in the survival analysisResults: During the study period, 38 children were diagnosed with medulloblastoma. Twenty-one of the patients were male (55.3%) and 17 were female (44.7%). The ages of the children ranged from 3 months to 17 years (median age 8 years). The ages of five patients were under 3 years (13.1%). The most common complaints were headache (n: 26, 68.4%), imbalance (n: 21, 55.3%), and vomiting (n: 20, 52.6%). The mass sizes ranged between3 and 6 cm in 32 patients (84.2%). At the time of diagnosis, 5 patients had seeding metastasis (13.1%). The most commonlyused chemotherapy protocol included vincristine, cisplatin, etoposide (60.5%). Five patients died after surgery without any chemotherapy or radiotherapy. Of the 33 patients included in the life analysis, 12 died (36.4%).Follow-up times ranged from 2 months to 14 years (median, 44 months). The overall survival rate was 59.1%. Eight patients had relapsed (24.2%). Late relapse was detected in 3 of the relapsed patients (relapse times were the 91st, 69th, and 72nd months). Conclusions: It is possible to achieve satisfactory treatment results in children with medulloblastoma using international treatment guidelines and recommendations, with an experienced professional team dedicated to pediatric neurooncology.
背景:髓母细胞瘤是儿童时期最常见的中枢神经系统肿瘤。本研究旨在评价诊断为成神经管细胞瘤的儿童患者的临床特征、治疗方法和结局。材料和方法:回顾性分析2006年至2019年儿童成神经管细胞瘤的医疗记录。手术后、化疗或放疗前死亡的患者不包括在生存分析中。结果:在研究期间,38名儿童被诊断为成神经管细胞瘤。其中男性21例(55.3%),女性17例(44.7%)。儿童年龄从3个月到17岁不等(中位年龄8岁)。5例患者年龄在3岁以下(13.1%)。最常见的主诉是头痛(26例,68.4%)、身体失衡(21例,55.3%)和呕吐(20例,52.6%)。32例(84.2%)患者肿块大小在3 ~ 6cm之间。确诊时5例发生播散性转移(13.1%)。最常用的化疗方案包括长春新碱、顺铂、依托泊苷(60.5%)。5例患者在手术后死亡,未进行任何化疗或放疗。在纳入生命分析的33例患者中,12例死亡(36.4%)。随访时间从2个月到14年不等(中位44个月)。总生存率为59.1%。复发8例(24.2%)。3例晚期复发(复发时间分别为91、69、72个月)。结论:采用国际治疗指南和建议,拥有经验丰富的儿科神经肿瘤学专业团队,可以获得令人满意的治疗结果。
{"title":"The Treatment Outcomes in Children with Medulloblastoma","authors":"Buket Kara, H. Akbaş, Mürsel Düzova, H. Karabağlı, Y. Köksal","doi":"10.38092/JPA-2020-909489","DOIUrl":"https://doi.org/10.38092/JPA-2020-909489","url":null,"abstract":"Background: Medulloblastoma is the most common central nervous system tumor in childhood. This study aims to evaluate the clinical features, treatments, and outcomes of pediatric patients diagnosed with medulloblastoma\u0000Materials and Method:Between 2006 and 2019, the medical records of children with medulloblastoma were reviewed retrospectively. Patients who died after surgery, before chemotherapy or radiotherapy were not included in the survival analysis\u0000Results: During the study period, 38 children were diagnosed with medulloblastoma. Twenty-one of the patients were male (55.3%) and 17 were female (44.7%). The ages of the children ranged from 3 months to 17 years (median age 8 years). The ages of five patients were under 3 years (13.1%). The most common complaints were headache (n: 26, 68.4%), imbalance (n: 21, 55.3%), and vomiting (n: 20, 52.6%). The mass sizes ranged between\u00003 and 6 cm in 32 patients (84.2%). At the time of diagnosis, 5 patients had seeding metastasis (13.1%). The most commonlyused chemotherapy protocol included vincristine, cisplatin, etoposide (60.5%). Five patients died after surgery without any chemotherapy or radiotherapy. Of the 33 patients included in the life analysis, 12 died (36.4%).\u0000Follow-up times ranged from 2 months to 14 years (median, 44 months). The overall survival rate was 59.1%. Eight patients had relapsed (24.2%). Late relapse was detected in 3 of the relapsed patients (relapse times were the 91st, 69th, and 72nd months). \u0000Conclusions: It is possible to achieve satisfactory treatment results in children with medulloblastoma using international treatment guidelines and recommendations, with an experienced professional team dedicated to pediatric neurooncology.","PeriodicalId":118905,"journal":{"name":"The Journal of Pediatric Academy","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125261193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Evaluation of the Children with Renal Transplant: Single Centre Experience 儿童肾移植的评价:单中心经验
Pub Date : 2020-12-27 DOI: 10.38092/jpa-2020-760856
Muhammed Mustafa Özdemir, A. Pınarbaşı, Neslihan Günay, Aynur Gencer-Balaban, Sibel Yel, M. Poyrazoğlu, I. Dursun
Objective: This study aimed to evaluate patients with renal transplantation in terms of clinical and laboratory.parameters.Material and Methods: This study was performed retrospectively with records of 48 patients who underwent renaltransplantation before 18 years of age, between June 2008 and July 2019.Results: Congenital malformations of the urinary tract were the most common underlying causes of chronic kidneydisease stage 5. Surgical complications occurred in 33.4% of the patients and BK viremia was the most commonopportunistic viral infection during the follow-up. At the last clinic visit, 57.4% of our patients had CKD stage 1,hypertension and nephrotic range proteinuria were seen in eight and two patients, respectively.Conclusion: Although renal transplantation is the most ideal renal replacement therapy, patients may experiencevarious complications during the follow-up. Therefore, they should be monitored regularly
材料与方法:本研究回顾性分析了2008年6月至2019年7月期间48例18岁前肾移植患者的临床和实验室参数。结果:泌尿道先天性畸形是慢性肾脏疾病5期最常见的潜在原因。手术并发症发生率为33.4%,BK病毒血症是最常见的机会性病毒感染。在最后一次门诊就诊时,57.4%的患者为CKD 1期,高血压和肾病范围蛋白尿分别见于8例和2例。结论:肾移植是最理想的肾脏替代治疗方法,但患者在随访过程中可能出现各种并发症。因此,他们应该定期监测
{"title":"The Evaluation of the Children with Renal Transplant: Single Centre Experience","authors":"Muhammed Mustafa Özdemir, A. Pınarbaşı, Neslihan Günay, Aynur Gencer-Balaban, Sibel Yel, M. Poyrazoğlu, I. Dursun","doi":"10.38092/jpa-2020-760856","DOIUrl":"https://doi.org/10.38092/jpa-2020-760856","url":null,"abstract":"Objective: This study aimed to evaluate patients with renal transplantation in terms of clinical and laboratory.\u0000parameters.\u0000Material and Methods: This study was performed retrospectively with records of 48 patients who underwent renal\u0000transplantation before 18 years of age, between June 2008 and July 2019.\u0000Results: Congenital malformations of the urinary tract were the most common underlying causes of chronic kidney\u0000disease stage 5. Surgical complications occurred in 33.4% of the patients and BK viremia was the most common\u0000opportunistic viral infection during the follow-up. At the last clinic visit, 57.4% of our patients had CKD stage 1,\u0000hypertension and nephrotic range proteinuria were seen in eight and two patients, respectively.\u0000Conclusion: Although renal transplantation is the most ideal renal replacement therapy, patients may experience\u0000various complications during the follow-up. Therefore, they should be monitored regularly","PeriodicalId":118905,"journal":{"name":"The Journal of Pediatric Academy","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127039423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can Phototherapy Requirements Be Predicted through Cord Blood Test Results in Newborns? 新生儿脐带血检查结果可以预测光疗需求吗?
Pub Date : 2020-12-27 DOI: 10.38092/JPA-2020-48192
B. Hekimoğlu
Objective: Hyperbilirubinemia is one of the common problems in newborns. If not diagnosed and treated in time, high bilirubin levels can cause kernicterus and permanent brain damage. Therefore, early detection of hyperbilirubinemia development risk in newborns is important. Our aim is to determine whether the cord blood bilirubin level and the direct coombs test can be used as determinant parameters in order to predict babies with a high risk of developing hyperbilirubinemia requiring treatment.Material and Method: During the process of creating a hyperbilirubinemia follow-up protocol at Ordu University Training and Research Hospital, 300 babies born between January -June 2014with a birth weight ≥ 2500 g and gestational week ≥ 37 weeks were included in the study. The results of the cord blood bilirubin in of these babies, direct coombs test, maternal and infant blood groups and serum bilirubin levels of those who were hospitalized for phototherapy treatment within the first 24 hours were analyzed retrospectively.Results: Phototherapy was given to 35 of 300 (11.7%) newborns included in the study within the first 24 hours after birth. Direct coombs test was positive in 25 of them (8.3%). Phototherapy was given to 80% (n: 20) of the cases whose direct coombs test was positive. ABO incompatibility was found in the etiology of 51.5% of the cases with hyperbilirubinemia. It has been observed that patients with positive direct coombs test have a high rate of hospitalization (p<0.001). Cord blood bilirubin levels were found to be statistically higher in cases who received phototherapy (2.7±1.0 and 1.8±0.6, respectively, p<0.01). In determining the need for phototherapy, sensitivity was 77.1%, specificity was 77.0%, and negative predictive value was 96% for the cut off value of 2.0 mg/dl of cord blood bilirubin.Conclusion: Cord blood bilirubin level and direct coombs test are useful in predicting the possibility of pathological hyperbilirubinemia and hospitalization in newborns. Thus, detection of risky newborns with a noninvasive method within a few hours after birth will prevent early discharge and provide close follow-up and early treatment.
目的:高胆红素血症是新生儿常见病之一。如果不及时诊断和治疗,高胆红素水平会导致核黄疸和永久性脑损伤。因此,早期发现新生儿高胆红素血症的发展风险是很重要的。我们的目的是确定脐带血胆红素水平和直接梳子试验是否可以作为决定参数,以预测高胆红素血症需要治疗的高风险婴儿。材料与方法:在奥尔都大学培训与研究医院制定高胆红素血症随访方案的过程中,纳入了2014年1月至6月出生的300例婴儿,出生体重≥2500 g,孕周≥37周。回顾性分析住院光疗患者24小时内脐带血胆红素、直接coombs试验、母婴血型及血清胆红素水平。结果:纳入研究的300名新生儿中有35名(11.7%)在出生后24小时内接受了光疗。直接coombs试验阳性25例(8.3%)。直接coombs试验阳性的80% (n: 20)病例给予光疗。51.5%的高胆红素血症患者的病因为ABO血型不合。直接coombs试验阳性患者住院率高(p<0.001)。光疗组脐带血胆红素水平高于光疗组(分别为2.7±1.0和1.8±0.6,p<0.01)。在确定是否需要光疗时,脐带血胆红素2.0 mg/dl的临界值敏感性为77.1%,特异性为77.0%,阴性预测值为96%。结论:脐带血胆红素水平及直接coombs试验可用于预测新生儿病理性高胆红素血症及住院的可能性。因此,在出生后几小时内用无创方法发现危险新生儿,可以防止早期出院,并提供密切的随访和早期治疗。
{"title":"Can Phototherapy Requirements Be Predicted through Cord Blood Test Results in Newborns?","authors":"B. Hekimoğlu","doi":"10.38092/JPA-2020-48192","DOIUrl":"https://doi.org/10.38092/JPA-2020-48192","url":null,"abstract":"Objective: Hyperbilirubinemia is one of the common problems in newborns. If not diagnosed and treated in time, high bilirubin levels can cause kernicterus and permanent brain damage. Therefore, early detection of hyperbilirubinemia development risk in newborns is important. Our aim is to determine whether the cord blood bilirubin level and the direct coombs test can be used as determinant parameters in order to predict babies with a high risk of developing hyperbilirubinemia requiring treatment.\u0000Material and Method: During the process of creating a hyperbilirubinemia follow-up protocol at Ordu University Training and Research Hospital, 300 babies born between January -June 2014with a birth weight ≥ 2500 g and gestational week ≥ 37 weeks were included in the study. The results of the cord blood bilirubin in of these babies, direct coombs test, maternal and infant blood groups and serum bilirubin levels of those who were hospitalized for phototherapy treatment within the first 24 hours were analyzed retrospectively.\u0000Results: Phototherapy was given to 35 of 300 (11.7%) newborns included in the study within the first 24 hours after birth. Direct coombs test was positive in 25 of them (8.3%). Phototherapy was given to 80% (n: 20) of the cases whose direct coombs test was positive. ABO incompatibility was found in the etiology of 51.5% of the cases with hyperbilirubinemia. It has been observed that patients with positive direct coombs test have a high rate of hospitalization (p<0.001). Cord blood bilirubin levels were found to be statistically higher in cases who received phototherapy (2.7±1.0 and 1.8±0.6, respectively, p<0.01). In determining the need for phototherapy, sensitivity was 77.1%, specificity was 77.0%, and negative predictive value was 96% for the cut off value of 2.0 mg/dl of cord blood bilirubin.\u0000Conclusion: Cord blood bilirubin level and direct coombs test are useful in predicting the possibility of pathological hyperbilirubinemia and hospitalization in newborns. Thus, detection of risky newborns with a noninvasive method within a few hours after birth will prevent early discharge and provide close follow-up and early treatment.","PeriodicalId":118905,"journal":{"name":"The Journal of Pediatric Academy","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116296171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
SARS-CoV-2 Infection in Children; What Do We Know So Far? 儿童SARS-CoV-2感染;到目前为止我们知道什么?
Pub Date : 2020-12-27 DOI: 10.38092/jpa-2020-849794
B. Cetin
After Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV), SARS-CoV-2 is the newest member of the family of coronaviruses that are pathogenic to humans. The disease which occurs with SARS-CoV-2 is called coronavirus disease 2019 (COVID-19). COVID-19 was first described in December 2019 and has caused millions of people to get sick and hundreds of thousands of deaths over the past year. In this review, the epidemiology, diagnosis, clinical and aboratory features, radiological findings, treatment, and management of the disease are all reviewed from a pediatrician’s perspective. Post-infectious complications, the impact of COVID-19 on global child health, and vaccine developments were also discussed in this review.
继严重急性呼吸综合征冠状病毒(SARS-CoV)和中东呼吸综合征冠状病毒(MERS-CoV)之后,SARS-CoV-2是冠状病毒家族中对人类致病的最新成员。与SARS-CoV-2一起发生的疾病被称为2019冠状病毒病(COVID-19)。COVID-19于2019年12月首次被描述,在过去一年中已导致数百万人生病,数十万人死亡。在这篇综述中,从儿科医生的角度回顾了该病的流行病学、诊断、临床和实验室特征、放射学表现、治疗和管理。本综述还讨论了感染后并发症、COVID-19对全球儿童健康的影响以及疫苗的发展。
{"title":"SARS-CoV-2 Infection in Children; What Do We Know So Far?","authors":"B. Cetin","doi":"10.38092/jpa-2020-849794","DOIUrl":"https://doi.org/10.38092/jpa-2020-849794","url":null,"abstract":"After Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV), SARS-CoV-2 is the newest member of the family of coronaviruses that are pathogenic to humans. The disease which occurs with SARS-CoV-2 is called coronavirus disease 2019 (COVID-19). COVID-19 was first described in December 2019 and has caused millions of people to get sick and hundreds of thousands of deaths over the past year. In this review, the epidemiology, diagnosis, clinical and aboratory features, radiological findings, treatment, and management of the disease are all reviewed from a pediatrician’s perspective. Post-infectious complications, the impact of COVID-19 on global child health, and vaccine developments were also discussed in this review.","PeriodicalId":118905,"journal":{"name":"The Journal of Pediatric Academy","volume":"50 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124401580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
The Journal of Pediatric Academy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1